Certus Critical Care Inc, a medical device company developing AI-enabled endo-aortic catheters for the treatment of stroke, catastrophic hemorrhage and cardiac arrest has just been awarded two grants totaling $3.1 million from the Department of Defense (DOD), according to their announcement.
The first of two grants included a $1.2 million non-dilutive equity grant that will enable the continued development of Certus’ Endovascular Variable Aortic Catheter (EVAC). EVAC is a next generation endovascular device with automated functionality for precision blood pressure control. The initial FDA use indication will be for hemorrhagic shock. The EVAC System consists of both an endovascular catheter and automated controller. The catheter is a low-profile endovascular device that uses precision sensors and adaptive algorithms to salvage patients affected by profound shock from blood loss.
Additional plans for precision blood pressure control in the setting of cardiac arrest and acute ischemic stroke are in development. Not only will the EVAC system serve U.S. warfighters in austere environments, but EVAC will be a game changer for stabilizing critically injured patients in well-resourced civilian trauma centers.
Additionally, Certus was awarded a $1.9 million grant from the DOD for continued development of their advanced ventilator analytics monitor. The Vent Right Monitor (VRM) is a next-generation inline device to both monitor, analyze, and provide clinical decision support for patients receiving invasive mechanical ventilation in the intensive care unit, the emergency department, or in the prehospital environment. The VRM’s advanced ventilator-patient asynchrony detection software will ensure fewer harmful interactions between patients and mechanical ventilators. The result will be fewer days in the ICU and fewer patient complications.
